TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03062930

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Track 1
Description: Training of non-paretic arm followed by sham condition

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Track 1
Description: Training of non-paretic arm followed by sham condition

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Track 2
Description: Same procedures as track 1, but completed in opposite order, starting with sham condition followed by the non-paretic arm training

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Track 2
Description: Same procedures as track 1, but completed in opposite order, starting with sham condition followed by the non-paretic arm training
Study: NCT03096314

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: 540,000 IU vitamin D3 delivered as a single, liquid enteral dose administered either orally or via naso/orogastric tube

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A single, liquid enteral dose identical in appearance and consistency to cholecalciferol administered either orally or via naso/orogastric tube.
Study: NCT01397877

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BKM120
Description: per os, 60mg/j, until progression or unacceptable toxicity
Study: NCT00728819

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-tapered PICC
Description: Standard peripheral central catheter placement in the Brachial, Basilic or Cephalic veins
Study: NCT02829320

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1278863
Description: GSK1278863 will be provided as round, standard biconvex, white film coated tablets containing 1 mg, 2 mg, 4 mg or 6 mg of GSK1278863 as active ingredient.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron
Description: Subjects will receive supplemental iron therapy if ferritin is \<=100 ng/mL and TSAT is \<=20%. The investigator (or subinvestigator) will choose the route of administration and dose of prescription iron.
Study: NCT03326570

Intervention type: BEHAVIORAL
Intervention: Medical Data Collection
Description: Medical information collected after bronchoscopy for up to 2 years.
Study: NCT02841995

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belumosudil (KD025)
Description: Pharmaceutical form: Capsules or Tablets Route of administration: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belumosudil (KD025)
Description: Pharmaceutical form: Capsules or Tablets Route of administration: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belumosudil (KD025)
Description: Pharmaceutical form: Capsules or Tablets Route of administration: Oral
Study: NCT01411800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 250 mg capsule
Description: Two 250 mg capsules will be administered for 500 mg dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 250 mg tablets
Description: Two 250 mg tablets will be administered for a 500 mg dose
Study: NCT01504464

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mesenchymal stem cell
Description: intra articular injection of mesenchymal stem cell

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Patients with knee joint osteoarthritis who underwent intra articular placebo injection
Study: NCT03448419

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Description: Film-coated tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Film-coated tablet
Study: NCT01506401

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SensorMedics 3100B High Frequency Oscillatory Ventilator
Description: High Frequency Oscillation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lung Protective Ventilation
Description: Tidal Volume 6ml/kg; plateau pressure \< or = 35cmH20; Prescribed PEEP/FiO2 chart
Study: NCT02348918

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Luminate 1.0mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Luminate 1.0mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Luminate 1.0mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Luminate 2.0mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Luminate 3.0mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Avastin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Avastin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Avastin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Avastin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Avastin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Luminate 0.5mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Luminate 0.5mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Luminate 0.5mg
Study: NCT02213172

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bifidobacterium longum R0175

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus paracasei HA-196
Study: NCT02003001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin
Study: NCT02564523

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.ZEBOV
Description: One 0.5 mL intramuscular (IM) injection of (5x10\*10 viral particles)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.ZEBOV
Description: One 0.5 mL intramuscular (IM) injection of (5x10\*10 viral particles)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.ZEBOV
Description: One 0.5 mL intramuscular (IM) injection of (5x10\*10 viral particles)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-BN-Filo
Description: One 0.5 mL IM injection of (1x10\*8 infectious units)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-BN-Filo
Description: One 0.5 mL IM injection of (1x10\*8 infectious units)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-BN-Filo
Description: One 0.5 mL IM injection of (1x10\*8 infectious units)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: One 0.5 mL IM injection of 0.9% saline

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: One 0.5 mL IM injection of 0.9% saline

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: One 0.5 mL IM injection of 0.9% saline
Study: NCT02414893

Intervention type: PROCEDURE
Intervention: Sleeve gastrectomy
Description: Laparoscopic vertical gastrectomy as a bariatric procedure.
Study: NCT02213172

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02343939

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entospletinib
Description: Tablet(s) administered orally every 12 hours
Study: NCT03892681

Intervention type: OTHER
Group type: OTHER
Intervention: hepatocyte-specific contrast agent, extracellular contrast agent
Description: The type of contrast agent for the 1st MRI will be performed using hepatocyte-specific contrast agent (Primovist). The participant will undergo the 2nd MRI using extracellular contrast agent (Gadovist).
Study: NCT04108377

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roflumilast
Description: Roflumilast capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar pill manufactured to mimic look of Roflumilast capsule
Study: NCT04532541

Intervention type: OTHER
Intervention: Monogenic lupus screening
Description: This is an observational study, and there is no intervention. This study intends to obtain the incidence of monogenic lupus in childhood onset SLE through gene test and bioinformatic analysis.
Study: NCT01548469

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bio Mineral toothpaste
Description: Frequency: 2 times everyday/Duration: 4 weeks/Dosage: 1ml at once

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Perio Total Care toothpaste
Description: Frequency: 2 times everyday/Duration: 4 weeks/Dosage: 1ml at once
Study: NCT00289627

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ipilimumab (MDX-010, BMS-734016)
Description: IV solution, IV, 10 mg/kg, Q 3 wks for 12 wks then Q 12 wks, 48+ weeks depending on response.
Study: NCT02751333

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: FCSEMS with Endostitch (ES)
Description: The fixation of FCSEMS using endostitch (ES) with the OverStitchTM system to prevent migration.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: FCSEMS with No Suturing (NS)
Description: The insertion of FCSEMS with no suturing.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fully Covered Self-Expanding Metal Stents (FCSEMS)
Description: This is the stent that will be used to treat the esophageal pathology in both groups

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fully Covered Self-Expanding Metal Stents (FCSEMS)
Description: This is the stent that will be used to treat the esophageal pathology in both groups

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EndoStitch (ES) with the OverStitchTM system
Description: This is the device used to apply the stitches to the stent in participants randomized to stent suturing.
Study: NCT02457624

Intervention type: BEHAVIORAL
Intervention: Education and feedback
Description: Experienced endoscopists will receive education on Kimura-Takemoto classification and feedback for their answers for classification tests.
Study: NCT01501383

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VX-765 Part A
Description: Tablets of VX-765 given at different doses based on treatment group in Part A

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VX-765 Part A
Description: Tablets of VX-765 given at different doses based on treatment group in Part A

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VX-765 Part A
Description: Tablets of VX-765 given at different doses based on treatment group in Part A

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VX-765 Part A
Description: Tablets of VX-765 given at different doses based on treatment group in Part A

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VX-765 Part B
Description: Tablets of VX-765 given at different doses based on patients who meet the study eligibility criteria for Part B
Study: NCT02796196

Intervention type: OTHER
Intervention: Medical Chart Review
Description: Review of medical chart

Intervention type: DEVICE
Intervention: Monitoring Device
Description: Wearable physical activity monitoring device

Intervention type: PROCEDURE
Intervention: Physical Therapy
Description: Undergo primarily self-directed physical therapy
Study: NCT00903890

Intervention type: OTHER
Intervention: Survey
Description: Survey asking questions regarding the subjects cardiac and general health.
Study: NCT03113058

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Adoptive transfer of γδT cells
Description: Patients are treated via intravenous infusion of in vitro-activated allogeneic γδ Tcells every two weeks, 12 times in total (6 months).
Study: NCT04109157

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: 20-minute pad test
Description: Our 20-minute modified pad test was described previously proposed first by Hahn and Fall and modified by Sand and Ostergard. Each patient's bladder was emptied with a transurethral catheter and filled to the SD amount of sterile water for test. The catheter was removed, and then the patient returned to a standing position with a pre-weighed perineal pad placed on the underwear. The patient was asked to cough 10 times, bear down 10 times, do 10 deep knee bends, jump up and down on the spot 10 times, wash her hands under cold water for 1 minute, walk up and down five stairs 10 times, walk in the hall for 10 minute, and then return for removal of the pad. The pad was then weighed and the net weight was calculated by subtracting from the original dry weight to achieve a measure of the total urine loss during the 20 minute exercise. The pad weight was measured in grams and the accuracy of the scale was 1 gram. The positive pad weight result was defined as more than 1 gram of leakage.
Study: NCT03293927

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: The patient will receive IV fentanyl

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: The patient will receive IV fentanyl

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: The patient will receive IV fentanyl

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: The patient will receive IV dexemedetomidine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: The patient will receive IV dexemedetomidine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: The patient will receive IV dexemedetomidine
Study: NCT02343939

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entospletinib
Description: Tablet(s) administered orally every 12 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entospletinib
Description: Tablet(s) administered orally every 12 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin
Description: 60 mg/m\^2 administered intravenously daily on Days 1 to 3 for up to two 14-day induction cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: 100 mg/m\^2 administered intravenously daily on Days 1 to 7 for up to two 14-day cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: 20 mg/m\^2 administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: 75 mg/m\^2 administered intravenously or subcutaneously
Study: NCT02770794

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab
Description: Discontinue infliximab; receive Infliximab when relapse
Study: NCT01200147

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: study withdrawn no details
Study: NCT00754104

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-869
Description: 0.25 mg/kg. daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tarceva
Description: 150mg, daily.
Study: NCT03131843

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alcohol
Description: Alcohol cleansing swab/wipe

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: No alcohol
Description: No alcohol will be used; alcohol cleansing swab/wipe will be used at a different injection site
Study: NCT01438905

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Small amplitude (Grade IV) mobilization
Description: The subject will be in a seated position and the therapist will stabilize the distal tibia with one hand and make contact the anterior talus with the opposite hand. Three 60-second anterior to posterior joint mobilizations of the talus (small amplitude at end range; Grade IV) will be applied by the therapist with one minute rest in between sets.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High velocity, low amplitude (Grade V) mobilization
Description: The subject will be in a seated position and the therapist will grasp the dorsum of the foot with their fingers. The ankle will be dorsiflexed until the restrictive barrier is reached. A small amplitude, quick thrust at end of range (High velocity, low amplitude; Grade V mobilization/manipulation) will be applied. If joint cavitation is not felt or heard by the therapist or subject the technique will be repeated one additional time.
Study: NCT01610089

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: stable isotope infusion
Description: Control subjects: \[15N2-ureido\] arginine (0.69 mg/kg); \[5-13C,4,4,5,5-D4\] citrulline (0.18mg/kg); 15N citrulline (0.03mg/kg); 15N sodium nitrate (0.003 mg/kg), \[15N\]\[18O3\] potassium nitrate (0.03 mg/kg) and \[18O\]\[13C\]urea (1 mg/kg)over 10 minutes. Followed by a 8-hour infusion of \[15N2-ureido\] arginine (0.69 mg/kg/hr); \[5-13C,4,4,5,5-D4\] citrulline (0.18mg/kg/hr), \[15N\]\[18O3\] potassium nitrate (0.003 mg/kg/hr) and \[18O\]\[13C\]urea (0.1 mg/kg/hr).~Citrullinemia type 1 subjects,\[15N2-ureido\] arginine (4.14 mg/kg); \[5-13C,4,4,5,5-D4\] citrulline (1.08 mg/kg); 15N citrulline (0.18mg/kg); 15N sodium nitrate (0.003 mg/kg), \[15N\]\[18O3\] potassium nitrate (0.03 mg/kg) and \[18O\]\[13C\]urea (1 mg/kg)over 10 minutes, followed by a 8-hour infusion of \[15N2-ureido\] arginine (4.14 mg/kg/hr); \[5-13C,4,4,5,5-D4\] citrulline (1.08 mg/kg/hr), \[15N\]\[18O3\] potassium nitrate (0.003 mg/kg/hr) and \[18O\]\[13C\]urea (0.1 mg/kg/hr).
Study: NCT02359955

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: zero degree teeth
Description: zero degree teeth complete denture was first prescribed to patients in group 1 while patients in group 2 were treated with anatomic teeth complete denture

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: zero degree teeth
Description: zero degree teeth complete denture was first prescribed to patients in group 1 while patients in group 2 were treated with anatomic teeth complete denture

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: anatomic teeth
Description: when anatomic teeth complete denture was prescribed to patients in group 1, patients in group 2 were treated with zero degree teeth complete denture

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: anatomic teeth
Description: when anatomic teeth complete denture was prescribed to patients in group 1, patients in group 2 were treated with zero degree teeth complete denture
Study: NCT03550755

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V3-Cervix
Description: Oral tableted preparation containing hydrolyzed tumor antigens derived from peripheral blood and tumor tissue
Study: NCT00891020

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tocilizumab [RoActemra/Actemra]
Description: 8 mg/kg intravenous every 4 weeks for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tocilizumab [RoActemra/Actemra]
Description: 8 mg/kg intravenous every 4 weeks for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tocilizumab [RoActemra/Actemra]
Description: 8 mg/kg intravenous every 4 weeks for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tocilizumab [RoActemra/Actemra]
Description: 4 mg/kg every 4 weeks for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nonbiologic DMARDs of investigator's choice
Description: Nonbiologic disease-modifying antirheumatic drugs (DMARDs) As prescribed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nonbiologic DMARDs of investigator's choice
Description: Nonbiologic disease-modifying antirheumatic drugs (DMARDs) As prescribed
Study: NCT01124994

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic mucosal resection
Description: Confocal laser endomicroscopy will be used to target endoscopic mucosal resection of Barrett's oesophagus-associated neoplasia
Study: NCT01256450

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Description: buccal soluble film; applied to the buccal mucosa twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: buccal soluble film; applied to the buccal mucosa twice daily
Study: NCT00857987

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EMS Expectorant
Description: Guaifenesin - 100mg, Etafedrine hydrochloride 20mg, Succinate doxilamine 6mg.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vehicle
Study: NCT01279317

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo co-ingestion
Description: 25 ml water co-ingested with a glucose-containing beverage

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vinegar co-ingestion
Description: 25 ml vinegar (1 g acetic acid) co-ingested with a glucose-containing beverage
Study: NCT01438398

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Submucosal endoscopic myotomy with mucosal flap technique
Description: Submucosal Endoscopy with Mucosal Flap (SEMF) technique involves the following: (1) injecting 0.9 % normal saline solution to create a submucosal cushion, (2) tiny cut is made into the cushion, (3) Balloon will be used to dilate the opening and allow passage of endoscope in the submucosal space, (4) Upon direct visualization of the muscle fibers, the doctor will cut the circular layers of the diseased muscles, and (5) Tiny clips will be used to close the tiny cut made earlier.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Submucosal Endoscopic Mucosal Flap (SEMF) technique
Study: NCT04120259

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin Oral Tablet
Description: A biguanide drug used as a first line therapy for Diabetes MellitusType 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin Oral Tablet
Description: A biguanide drug used as a first line therapy for Diabetes MellitusType 2

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vinegar
Description: A common herbal/dietary supplement used for centuries as an anti bacterial, cleaning,cooking, anti diabetic agent, to name a few uses.
Study: NCT02585947

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir
Description: Anti-HBc positive patients with Non-Hodgkin's lymphoma planned to receive rituximab based chemotherapy will be randomized to either Group A or Group B in a 1:1 ratio and will be monitored every 12 weeks from the start of treatment for up to 72 weeks after the end of chemotherapy (EOC).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir
Description: Anti-HBc positive patients with Non-Hodgkin's lymphoma planned to receive rituximab based chemotherapy will be randomized to either Group A or Group B in a 1:1 ratio and will be monitored every 12 weeks from the start of treatment for up to 72 weeks after the end of chemotherapy (EOC).
Study: NCT01547260

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemzar
Description: Gemcitabine (Gemzar®), 1000 mg/m2 in 0.9% sodium chloride will be administered as intravenous infusion over 30 minutes, weekly for 3 weeks then rest for 1 week (days 1, 8, 15 of each 28-day cycle).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Revlimid
Description: Lenalidomide capsules will be taken orally in the morning each day on days 1-21 of each 28-day cycle. Phase I; Three subjects will be enrolled into each dose cohort for 15, 20 and 25 mg/day, respectively. Phase II; Lenalidomide at dose determined in Phase I, will be administered orally once daily for 21 days followed by 7 days rest.
Study: NCT02892890

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Muscle Magnetic Resonance Imaging (RMI) evaluation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI